YOLFTbeta
Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc

MIST · NASDAQ · Healthcare / Biotechnology

0.52USD-0.14 (-20.63%)

Price History

Full chart

Market Stats

Previous Close0.6552
Open0.70
Day Range0.50 – 0.70
52-Week Range0.7521 – 3.06
Volume3.92M
Market Cap99.03M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.65
Dividend Yield0.00%
Beta0.98
50-Day Avg1.08
200-Day Avg1.54

About

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Joseph G. Oliveto M.B.A.
  • Employees38
  • Headquarters1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6, USA
  • Websitehttps://www.milestonepharma.com

Leadership

  • Mr. Joseph G. Oliveto M.B.A.CEO, President & Executive Director · b. 1968
  • Mr. Amit HasijaCFO & Executive VP of Corporate Development · b. 1973
  • Dr. David B. Bharucha FACC, M.D., Ph.D.Chief Medical Officer · b. 1962
  • Dr. Philippe Douville M.B.A., Ph.D.Founder, Strategic Advisor & Member of Scientific Advisory Board · b. 1962
  • Mr. Jeffrey NelsonChief Operating Officer · b. 1981
  • Mr. David SandovalGeneral Counsel & Chief Compliance Officer · b. 1978
  • Mr. Roshan GirglaniVice President of Marketing
  • Mr. Jeff MooreVice President of Sales
  • Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.Chief Medical Advisor & Member of the Scientific Advisory Board · b. 1956
  • Dr. Guy RousseauSVP of Regulatory Affairs and Quality Management

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00015.00M15.00M5.00M1.00M01.55M
Growth (%)----0.00%-66.67%-80.00%-100.00%-
Cost of Revenue8.00K10.00K236.00K376.00K-480.00K598.00K646.00K114.00K
Gross Profit-8.00K-10.00K-236.00K-376.00K15.00M5.00M1.00M-646.00K1.43M
Gross Margin----2.51%100.00%100.00%100.00%-92.63%
Operating Expense8.26M23.81M57.65M50.33M58.07M64.64M62.10M41.46M63.92M
Operating Income-8.27M-23.82M-57.88M-50.71M-43.07M-59.64M-61.10M-42.10M-62.48M
Operating Margin----338.07%-287.15%-1192.84%-6109.80%--4041.72%
EBITDA-8.26M-23.36M-57.84M-50.61M-42.76M-59.55M-57.04M-37.83M-59.45M
EBITDA Margin----337.42%-285.07%-1191.06%-5703.90%--3845.47%
Net Income-8.09M-23.18M-55.23M-49.97M-42.85M-57.13M-59.69M-41.52M-63.06M
Net Income Margin----333.11%-285.69%-1142.68%-5968.50%--4078.78%
R&D5.64M16.85M42.38M34.86M38.67M39.83M31.05M14.36M18.11M
R&D as % of Total Revenue---232.41%257.81%796.58%3105.20%-1171.28%
Interest Expense002.60M726.00K220.00K1.25M2.55M3.58M3.84M
Interest Expense % of Total Revenue---4.84%1.47%25.08%255.40%-248.25%

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.59M88.08M123.43M149.97M119.85M74.48M75.23M75.50M113.56M
Total Liabilities60.71M143.29M8.51M6.86M7.25M8.13M58.45M62.35M71.79M
Total Equity-33.12M-55.21M114.92M143.12M112.60M66.35M16.77M13.15M41.77M
Cash10.88M85.95M119.82M72.31M114.14M7.64M13.76M25.31M73.05M
Total Debt--514.00K941.00K698.00K2.49M51.77M54.80M58.38M
Net Debt-10.88M-85.95M-119.30M-71.37M-113.44M-5.14M38.02M29.48M-14.67M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.05M-21.05M-51.15M-50.73M-33.22M-52.47M-46.42M-28.85M-49.04M
Investing Cash Flow-16.02M16.00M-384.00K-70.00M70.00M-57.12M4.76M8.28M11.25M
Financing Cash Flow30.72M80.11M85.41M73.22M5.05M3.09M47.79M32.12M85.53M
Capital Expenditure36.00K5.00K413.00K97.00K0272.00K112.00K33.00K302.00K
Free Cash Flow-8.09M-21.05M-51.56M-50.73M-33.22M-52.74M-46.54M-28.88M-49.34M
Dividends Paid00-------
FCF to OCF100.45%100.02%100.81%100.00%100.00%100.52%100.24%100.11%100.62%
Dividend Paid to FCF0.00%0.00%-------

Earnings

Report DateMay 24, 2019Aug 13, 2019Nov 13, 2019Mar 6, 2020May 14, 2020Aug 12, 2020Nov 13, 2020Mar 29, 2021May 17, 2021Aug 11, 2021Nov 12, 2021Mar 24, 2022May 12, 2022Aug 10, 2022Nov 10, 2022Mar 29, 2023May 11, 2023Aug 10, 2023Nov 13, 2023Mar 21, 2024May 13, 2024Aug 8, 2024Nov 12, 2024Mar 19, 2025May 14, 2025Aug 12, 2025Nov 12, 2025Mar 31, 2026May 13, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate-17.30-0.56-0.55-0.51-0.74-0.43-0.46-0.41-0.32-0.35-0.35-0.36-0.38-0.37-0.41-0.33-0.39-0.39-0.39-0.31-0.27-0.20-0.18-0.15-0.19-0.18-0.17-0.160.19-0.18-0.20
EPS Actual-0.41-0.56-0.52-0.63-0.67-0.53-0.40-0.13-0.300.02-0.34-0.40-0.33-0.39-0.34-0.31-0.35-0.37-0.35-0.32-0.21-0.14-0.14-0.19-0.31-0.20-0.12-0.15-0.20-0.21-
Surprise97.63%0.00%5.45%-23.53%9.46%-23.26%13.04%68.29%6.25%105.71%2.86%-11.11%13.16%-5.41%17.07%6.06%10.26%5.13%10.26%-3.23%22.22%30.00%22.22%-26.67%-63.16%-11.11%29.41%6.25%-205.26%-16.67%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap99.03M
Enterprise Value-3.22M
Trailing P/E0.00
Forward P/E0.00
Price / Sales42.26
Price / Book5.89
EPS-0.65
Book Value0.129
Revenue (TTM)2.34M
Gross Profit (TTM)2.30M
EBITDA-78.21M
Profit Margin0.00%
Operating Margin-4584.97%
Return on Equity-35522.62%
Return on Assets-42.78%
Shares Outstanding124.50M
Shares Float106.47M
Beta0.98
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 5.86
  • Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
50.57%
Insiders
0.70%
Retail / Other
48.73%

Top Institutional Holders

  • Propel Bio Management LLC
    7.43M5.97%
  • RTW INVESTMENTS, LLC
    6.33M5.09%
  • Simplify Asset Management Inc.
    3.35M2.69%
  • Millennium Management LLC
    3.14M2.52%
  • Two Sigma Investments LLC
    2.04M1.64%
  • The Goldman Sachs Group Inc
    2.00M1.61%
  • Marshall Wace Asset Management Ltd
    1.94M1.56%
  • Point72 Asset Management, L.P.
    1.09M0.87%
  • Balyasny Asset Management LLC
    851.33K0.68%
  • Lion Point Capital, LP
    820.00K0.66%
  • The Toronto-Dominion Bank
    750.00K0.60%
  • Morgan Stanley - Brokerage Accounts
    724.14K0.58%
  • Boxer Capital Management, LLC
    666.67K0.54%
  • Susquehanna International Group, LLP
    519.05K0.42%
  • UBS Group AG
    494.91K0.40%
  • Squarepoint Ops LLC
    336.82K0.27%
  • Seven Fleet Capital Management LP
    333.33K0.27%
  • GUARDIAN WEALTH ADVISORS, LLC / NC
    280.25K0.23%
  • Aptus Capital Advisors, LLC
    280.25K0.23%

Top Fund Holders

  • Simplify Propel Opportunities ETF
    3.35M2.69%